Group vs. Individual Metacognitive Therapy for Generalized Anxiety Disorder
Generalized Anxiety Disorder: A Randomized Non-inferiority Trial Comparing Group Metacognitive Therapy With Individual Metacognitive Therapy
Generalized anxiety disorder (GAD) is a serious and long-lasting condition that can greatly reduce quality of life, work functioning, and use of health services. Metacognitive therapy (MCT) is an effective treatment for GAD, but it is not yet known whether individual MCT or group-based MCT provides the best results for patients.
This randomized controlled trial will compare two formats of MCT: individual treatment and group-based treatment (g-MCT). A total of 64 adults with GAD (32 in each treatment arm) will participate after providing informed consent. Participants will complete questionnaires, undergo clinical assessments, and allow the study to collect relevant health information from official registries.
The main aim of the study is to determine whether group-based MCT is non-inferior to individual MCT. A non-inferiority design tests whether the group format is not meaningfully less effective than the individual format. If group MCT is shown to have similar effects on anxiety symptoms and functioning, it could offer an efficient and resource-saving alternative in routine clinical care.
This will be the first study to systematically compare these two treatment formats in a real-world clinical setting. If group MCT proves to be as effective as individual therapy, it may help increase access to evidence-based treatment for people with GAD, reduce strain on mental health services, and support the development of more accessible and cost-effective care.
研究概览
详细说明
Generalized anxiety disorder (GAD) is a chronic and disabling condition characterized by persistent and uncontrollable worry. Individuals with GAD frequently experience reduced quality of life, impaired daily functioning, and elevated use of health care services. Although effective psychological treatments exist, including metacognitive therapy (MCT), it remains unclear which treatment delivery format provides the best balance of clinical effectiveness and efficient use of resources.
MCT is an evidence-based treatment targeting the metacognitive processes that maintain excessive worry, including beliefs about the usefulness and uncontrollability of worrying and the cognitive-attentional syndrome (CAS), a pattern of worry, rumination, threat monitoring, and unhelpful coping behaviors. Individual MCT has demonstrated strong and consistent effects across several clinical trials, while group-based MCT (g-MCT) has shown promising preliminary results. However, the two formats have never been directly compared in a randomized trial conducted in routine clinical care. This represents a meaningful gap in the research literature and limits the ability of services to make informed decisions about how to organize treatment.
This study addresses this gap by conducting a randomized controlled trial (RCT) comparing individual MCT with group-based MCT for adults with GAD. An RCT design is chosen because it provides the highest level of evidence for causal inference about treatment effects. A non-inferiority framework is used to test whether group MCT is not meaningfully less effective than individual MCT. This design is appropriate when an alternative treatment may offer practical advantages-such as lower cost, greater accessibility, or more efficient resource use-while aiming to demonstrate that clinical outcomes remain comparable.
A total of 64 adults with a primary diagnosis of GAD will be enrolled and randomized to either individual MCT or group MCT. Both interventions follow established MCT protocols and are delivered by trained clinicians. Treatment focuses on reducing worry, modifying maladaptive metacognitive beliefs, and promoting flexible attentional control. Data collection includes validated self-report questionnaires, structured clinical assessments, and-with participant consent-information obtained from official national registers to assess work participation and sick leave pre and post treatment.
Evaluating group-based MCT is particularly important in the context of mental health services, where demand often exceeds available treatment resources. If group MCT is found to be non-inferior to individual MCT, it could make it possible to offer effective therapy to more patients within the same amount of therapist time. This has the potential to reduce waiting times, improve access to evidence-based treatment, and support more sustainable use of clinical resources.
The findings from this trial will contribute to the evidence base for MCT, clarify which treatment format is most appropriate for adults with GAD, and inform clinical guidelines and service organization. As the first randomized study to directly compare individual and group MCT in a real-world clinical setting, the results may have meaningful implications for both clinical practice and mental health policy.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Gunvor Launes, MD Phd
- 电话号码:+4747661428
- 邮箱:Gunvor.Launes@sshf.no
研究联系人备份
- 姓名:Anna Sorte Grindvik, MD
- 电话号码:+4797771807
- 邮箱:Anna.Sorte.Grindvik@sshf.no
学习地点
-
-
-
Kristiansand、挪威
- 招聘中
- Sørlandet Hospital HF
-
接触:
- Anna Grindvik, MD
- 邮箱:Anna.Sorte.Grindvik@sshf.no
-
-
Agder
-
Kristiansand、Agder、挪威
- 招聘中
- Sørlandet Hospital HF
-
接触:
- Anna Sorte Grindvik, MD
- 电话号码:+4797771807
- 邮箱:Anna.Sorte.Grindvik@sshf.no
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
Adults with a primary diagnosis of generalized anxiety disorder (GAD). GAD-7 score ≥ 10 at screening/baseline. Participants must endorse that they experience problems with excessive worry
Exclusion Criteria:
- Bipolar disorder;
- Psychosis;
- Ongoing substance abuse/dependence;
- Intellectual disability based on previous medical history;
- Eating disorder in need of medical attention;
- Unwillingness to refrain from anxiolytic drugs during the treatment;
- Current suicidal ideation with plan and intent;
- Taking an unstable dose of antidepressant, with recent dose-change within the last 4 weeks;
- Known cluster A or B personality disorder;
- Serious medical comorbidity (e.g.: cancer, severe renal failure)
- Language difficulties in need of an interpreter.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Individual Metacognitive Therapy (MCT)
Participants receive individual metacognitive therapy delivered by a trained clinician according to the established MCT protocol for generalized anxiety disorder.
Treatment is provided weekly for 10 weeks, each session lasting approximately 45 minutes.
|
Individual metacognitive therapy (MCT) is delivered by a trained clinician following the established protocol for generalized anxiety disorder.
The treatment focuses on modifying maladaptive metacognitive beliefs, reducing the cognitive-attentional syndrome (CAS), and promoting flexible attentional control.
Participants receive 10 weekly individual sessions, each lasting approximately 45 minutes.
The intervention targets excessive worry, unhelpful coping strategies, and beliefs about the uncontrollability and danger of worry.
|
|
实验性的:Group Metacognitive Therapy (g-MCT)
Participants receive group-based metacognitive therapy delivered by two trained clinicians according to the established group MCT protocol for generalized anxiety disorder.
Treatment is delivered in small groups of 4-6 participants meeting weekly for 10 weeks.
Each session lasts approximately 90 minutes.
|
Group Metacognitive Therapy (g-MCT) is delivered by two trained clinicians following the established group MCT protocol for generalized anxiety disorder.
Treatment is provided in small groups of 4-6 participants and focuses on modifying maladaptive metacognitive beliefs, reducing the cognitive-attentional syndrome (CAS), and improving attentional flexibility.
Participants attend 10 weekly sessions, each lasting approximately 90 minutes.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Generalized Anxiety Disorder-7 (GAD-7)
大体时间:Pre-treatment (baseline; one week before treatment start) mid-treatment A (the day after therapy session 4), mid-treatment B (The day after therapy session 7), post-treatment (one week after the last therapy session), 3-month follow-up, 12-month follow-u
|
The Generalized Anxiety Disorder-7 (GAD-7) is a validated 7-item self-report measure assessing the severity of generalized anxiety symptoms over the past two weeks.
Total scores range from 0 to 21, with higher scores indicating greater symptom severity.
The primary outcome is change in GAD-7 score from pre-treatment (baseline, one week before treatment start) to post-treatment (one week after the last therapy session) and 3- month and 12- month follow up.
The measure is widely used in clinical research and has demonstrated strong reliability, sensitivity to change, and clinical validity in GAD populations.
|
Pre-treatment (baseline; one week before treatment start) mid-treatment A (the day after therapy session 4), mid-treatment B (The day after therapy session 7), post-treatment (one week after the last therapy session), 3-month follow-up, 12-month follow-u
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Patient Health Questionnaire-9 (PHQ-9)
大体时间:Pre-treatment (baseline; one week before treatment start) mid-treatment A (the day after therapy session 4), mid-treatment B (The day after therapy session 7), post-treatment (one week after the last therapy sessio), 3-month follow-up, 12-month follow-up
|
The Patient Health Questionnaire-9 (PHQ-9) is a 9-item validated self-report measure of depressive symptom severity over the past two weeks.
Scores range from 0-27, with higher scores indicating more severe depressive symptoms.
|
Pre-treatment (baseline; one week before treatment start) mid-treatment A (the day after therapy session 4), mid-treatment B (The day after therapy session 7), post-treatment (one week after the last therapy sessio), 3-month follow-up, 12-month follow-up
|
|
Generalized Anxiety Disorder Scale-Revised (GADS-R)
大体时间:Pre-treatment (baseline; one week before treatment start) , one day before each therapy session session, post-treatment (one week after last therapy session), 3-month follow-up, 12-month follow-up.
|
The Generalized Anxiety Disorder Scale-Revised (GADS-R) is a self report questionaire assessing cognitive and behavioral symptoms of generalized anxiety disorder.
The scale measures worry severety and maladaptive coping strategies on a 9-point Likert scale (0-8), while metacognitive beliefs about worry are rated on a 0-100 scale.
Higher scores indicate greater symptom severity.
Secondary outcomes include change in GADS-R score from pre-treatment (baseline) to post-treatment, as well as repeated GADS-R assessments administered during treatment (prior to each therapy session) and at 3-month and 12-month follow-up, to monitor clinical change over time.
|
Pre-treatment (baseline; one week before treatment start) , one day before each therapy session session, post-treatment (one week after last therapy session), 3-month follow-up, 12-month follow-up.
|
|
Work and Social Adjustment Scale (WSAS)
大体时间:Pre-treatment (baseline; one week before treatment start) post-treatment (one week after the last therapy session), 3-month follow-up, and 12-month follow-up
|
The Work and Social Adjustment Scale (WSAS) is a 5-item self-report questionnaire assessing functional impairment in work, home management, social leisure, private leisure, and close relationships.
Scores range from 0-40, with higher scores indicating greater impairment.
Secondary outcomes include change in WSAS score from pre-treatment (baseline) to post-treatment (one week after the last therapy session), as well as WSAS scores at 3-month and 12-month follow-up.
|
Pre-treatment (baseline; one week before treatment start) post-treatment (one week after the last therapy session), 3-month follow-up, and 12-month follow-up
|
|
Metacognitions Questionnaire- 30 (MCQ-30)
大体时间:Pre-treatment (baseline; one week before treatment start), post-treatment (one week after the last therapy session), 3-month follow-up, and 12-month follow-up
|
The Metacognitions Questionnaire- 30 (MCQ-30) is a 30-item self-report measure assessing maladaptive metacognitive beliefs across five domains.Total scores range from 30 to 120, with higher scores indicating stronger dysfunctional metacognitive beliefs.
|
Pre-treatment (baseline; one week before treatment start), post-treatment (one week after the last therapy session), 3-month follow-up, and 12-month follow-up
|
|
Client Satisfaction Questionnaire (CSQ-8)
大体时间:Post-treatment (one week after the last therapy session)
|
The Client Satisfaction Questionnaire (CSQ-8) is an 8-item self-report measure assessing satisfaction with treatment.
Total scores range from 8 to 32, with higher scores indicating greater satisfaction.
|
Post-treatment (one week after the last therapy session)
|
|
Working Alliance Inventory - Short, Client Version (WAI-C-S)
大体时间:Mid-treatment A (the day after therapy session 4), mid-treatment B (the day after therapy session 7), and post-treatment (one week after the last therapy session).
|
The Working Alliance Inventory - Short, Client Version (WAI-C-S) is a 12-item validated measure assessing the therapeutic alliance across goals, tasks, and bond.
Total scores range from 12 to 84, with higher scores indicating a stronger therapeutic alliance.
|
Mid-treatment A (the day after therapy session 4), mid-treatment B (the day after therapy session 7), and post-treatment (one week after the last therapy session).
|
|
EQ-5D-5L
大体时间:Pre-treatment (baseline; one week before treatment start), post-treatment (one week after the last therapy session), 3-month follow-up, and 12-month follow-up.
|
The EQ-5D-5L is a standardized self-report measure assessing health-related quality of life across five domains and includes a visual analogue scale (VAS).
Higher scores indicate better perceived health.
|
Pre-treatment (baseline; one week before treatment start), post-treatment (one week after the last therapy session), 3-month follow-up, and 12-month follow-up.
|
|
Social Phobia Inventory (SPIN)
大体时间:Pre-treatment (baseline; one week before treatment start), post-treatment (one week after the last therapy session), 3-month follow-up, and 12-month follow-up
|
The Social Phobia Inventory (SPIN) is a 17-item measure evaluating fear, avoidance, and physiological symptoms of social anxiety.
Scores range from 0-68, with higher scores indicating greater social anxiety.
|
Pre-treatment (baseline; one week before treatment start), post-treatment (one week after the last therapy session), 3-month follow-up, and 12-month follow-up
|
|
Work Ability Score (WAS)
大体时间:Pre-treatment (baseline; one week before treatment start), post-treatment (one week after the last therapy session), 3-month follow-up, and 12-month follow-up
|
The Work Ability Score (WAS) is a single-item measure rating current work ability compared to lifetime best on a scale of 0-10.
Higher scores reflect better work ability.
|
Pre-treatment (baseline; one week before treatment start), post-treatment (one week after the last therapy session), 3-month follow-up, and 12-month follow-up
|
|
Clinical Severity Rating (CSR)
大体时间:Pre-treatment (baseline; one week before treatment start), post-treatment (1 week after the last therapy session), 12-month follow-up.
|
The Clinical Severity Rating (CSR) is a clinician-rated measure of overall diagnostic severity on a 0-8 scale, where higher scores indicate greater symptom severity and functional impairment.
An external, independent clinician (physician or psychologist not involved in treatment or study procedures) conducts a brief structured assessment with each participant.
The CSR evaluates both the primary diagnosis of generalized anxiety disorder (GAD) and any comorbid conditions, providing a standardized, observer-based measure of clinical severity and change over time.
|
Pre-treatment (baseline; one week before treatment start), post-treatment (1 week after the last therapy session), 12-month follow-up.
|
合作者和调查者
调查人员
- 首席研究员:Gunvor Launes, MD, PhD、Sørlandet Hospital HF
出版物和有用的链接
一般刊物
- Larsen DL, Attkisson CC, Hargreaves WA, Nguyen TD. Assessment of client/patient satisfaction: development of a general scale. Eval Program Plann. 1979;2(3):197-207. doi: 10.1016/0149-7189(79)90094-6. No abstract available.
- Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011 Dec;20(10):1727-36. doi: 10.1007/s11136-011-9903-x. Epub 2011 Apr 9.
- Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13. doi: 10.1046/j.1525-1497.2001.016009606.x.
- Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7. doi: 10.1001/archinte.166.10.1092.
- Mundt JC, Marks IM, Shear MK, Greist JH. The Work and Social Adjustment Scale: a simple measure of impairment in functioning. Br J Psychiatry. 2002 May;180:461-4. doi: 10.1192/bjp.180.5.461.
- Meyer TJ, Miller ML, Metzger RL, Borkovec TD. Development and validation of the Penn State Worry Questionnaire. Behav Res Ther. 1990;28(6):487-95. doi: 10.1016/0005-7967(90)90135-6.
- Wells A, Cartwright-Hatton S. A short form of the metacognitions questionnaire: properties of the MCQ-30. Behav Res Ther. 2004 Apr;42(4):385-96. doi: 10.1016/S0005-7967(03)00147-5.
- Connor KM, Davidson JR, Churchill LE, Sherwood A, Foa E, Weisler RH. Psychometric properties of the Social Phobia Inventory (SPIN). New self-rating scale. Br J Psychiatry. 2000 Apr;176:379-86. doi: 10.1192/bjp.176.4.379.
- Brown TA, Barlow DH: Anxiety and related disorders interview schedule for DSM-5 (ADIS-5)-adult and lifetime version: Clinician manual, Oxford University Press; 2014
- Lundin A, Leijon O, Vaez M, Hallgren M, Torgen M. Predictive validity of the Work Ability Index and its individual items in the general population. Scand J Public Health. 2017 Jun;45(4):350-356. doi: 10.1177/1403494817702759. Epub 2017 Apr 7.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- 931881
- PEIK 3797 (其他标识符:Sørlandet Sykehus HF)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.